1 Subjects: “...Biological Products / therapeutic use...”

2 “... and safety, as well as evidence-based clinical guidelines, on the practice of switching biologics, both...”

3 “... (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic...”

4 “... (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic...”

5 “... biologic or non-biologic disease-modifying antirheumatic drugs (DMARDs). Sarilumab is available in 150 mg...”

6 “... (BSC) and biologics in patients with active PsA whose disease was not adequately controlled or who were...”

7 “... (BSC) and biologics in patients with active PsA whose disease was not adequately controlled or who were...”

8 “... not be used in combination with other biologic DMARDs (bDMARDs) or Janus kinase (JAK) inhibitors...”

9 “... not be used in combination with other biologic DMARDs (bDMARDs) or Janus kinase (JAK) inhibitors...”

10 “... in combination with other biologic DMARDs (bDMARDs), including Janus kinase (JAK) inhibitors...”

11 “... discrete-event simulation model. The model compares numerous possible sequences of biologic treatments...”

12 “... in combination with other biologic DMARDs (bDMARDs), including Janus kinase (JAK) inhibitors...”

13 “... discrete-event simulation model. The model compares numerous possible sequences of biologic treatments...”

14 “... in patients 2 years and older who are contraindicated to, or have discontinued, any biologic therapy for lack...”

15 “... in patients 2 years and older who are contraindicated to, or have discontinued, any biologic therapy for lack...”

16

17

18 “... biologics, which tend to target specific cytokines. Upadacitinib is the third JAK inhibitor approved...”

19 “... biologics, which tend to target specific cytokines. Upadacitinib is the third JAK inhibitor approved...”

20